Marker therapeutics, inc. (MRKR)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash Flows from Operating Activities:
Net loss

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-14,678

-11,758

-10,982

-9,875

-7,993

-125

-2,455

-2,531

28,075

-38,115

-34,066

-33,150

-62,846

-1,876

-30,883

0

0

0

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,014

-6,171

0

0

0

Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization

129

105

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in fair value of warrant liabilities

-58

-18

22

-82

50

40

101

137

-9

-5

-23

-703

-8,932

-5,939

-6,538

-36,120

31,196

27,872

28,728

58,765

-666

-0

0

0

0

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Shares issued in debt settlement agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

181

-8

-104

-104

0

0

0

Non-cash interest and financing charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Stock-based compensation

5,175

5,356

18,476

18,143

17,740

16,350

2,353

3,187

2,498

2,738

2,582

1,660

1,720

1,558

2,752

2,001

1,915

1,705

387

840

704

1,391

1,276

819

738

132

131

262

2,360

2,440

0

0

0

Amortization on right-of-use assets

184

181

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,884

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest and finance charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Changes in fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,255

229

0

0

0

Loss on settlement of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Loss (gain) on settlement of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Gain on extinguishment of derivative liabilities- warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Loss on disposal of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Non-cash interest and finance charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and deposits

1,499

1,384

1,809

382

87

90

0

-70

-48

-18

-15

157

139

1

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest receivable

-87

-51

78

98

112

108

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Due from government agency

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-0

-0

0

0

0

Prepaid expenses and deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-111

-115

77

-41

0

0

0

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

27

30

-1

5

0

0

0

Accounts payable and accrued expenses

261

-963

-702

-620

420

1,241

1,831

2,034

851

283

78

23

-196

257

601

516

764

96

-231

-318

-294

-145

1,410

1,093

1,363

1,835

1,791

2,489

2,622

2,015

0

0

0

Lease liability

-189

-185

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability

-189

-185

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research agreement obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

76

126

170

140

156

0

0

0

Net cash used in operating activities

-18,503

-18,284

-19,886

-17,793

-16,013

-14,479

-10,795

-9,249

-8,862

-8,439

0

0

0

-

-

-

-

-

-

-3,403

-2,828

-2,187

-1,457

-686

-613

-694

-1,247

-1,384

-1,710

-1,588

0

0

0

Cash Flows from Investing Activities:
Purchase of property and equipment

251

374

509

453

370

147

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Cash acquired on reverse acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Net cash used in investing activities

-251

-374

-509

-453

-370

-147

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Cash Flows from Financing Activities:
Proceeds from exercise of stock options

-

57

57

57

57

18

18

18

18

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

1,303

758

768

97

4,359

4,353

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of shares, net of finders' fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

347

-235

0

331

335

705

555

0

0

0

Repayment of promissory note

-

-

-

-

-

-

-

-

-

-

-

-

-

-25

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from loans payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32

-18

-15

3

3

0

0

0

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible note issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,156

738

1,330

838

602

602

0

0

0

Notes and loans payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Advances from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Repayment of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

0

0

0

-

-

-

-

Stock subscriptions

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Net cash provided by financing activities

1,303

816

64,579

63,908

71,290

71,245

7,482

7,069

5,735

5,717

0

0

0

-

-

-

-

-

-

6,488

4,188

2,280

2,066

661

702

709

1,248

1,417

1,691

1,372

0

0

0

Net decrease in cash

-17,451

-17,842

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash

-

-

-

-

-

-

-

-

-3,126

-2,721

-1,979

6,194

205

1,274

3,499

662

4,268

6,434

5,473

3,084

1,359

93

608

-24

89

14

1

33

-19

-216

0

0

0

Supplemental schedule of non-cash financing activities:
Issuance of common stock as commitment fee for future financing

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilsons compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

191

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of issuance of warrants in January and March 2015 financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,313

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable settled in common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,415

0

0

0

-

-

-

-

-

-

-

-

Fair value of issuance of warrants in January an March 2015 financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

525

0

0

0

-

-

-

-

-

-

-

-

Convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,116

0

0

0

-

-

-

-

-

-

-

-

Loans payable, related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

0

0

0

-

-

-

-

-

-

-

-

Promissory notes, related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

210

0

0

0

-

-

-

-

-

-

-

-

Due to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

369

0

0

0

-

-

-

-

-

-

-

-

Fair value derivative liability - conversion opt at conversion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

708

0

0

0

-

-

-

-

-

-

-

-

CASH, BEGINNING OF YEAR

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

CASH, END OF YEAR

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

CASH, END OF PeriodPERIOD

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0